Locate red-cell destruction, interpret immune testing, and distinguish inherited defects, complement injury and urgent fragmentation syndromes.
Dark urine, jaundice and anemia suggest a red-cell problem, but none identifies the mechanism alone. First establish accelerated RBC destruction. Then ask where cells are lost, whether an immune coating is involved, and which intrinsic or external injury explains the pattern.
Prove destruction before naming a hemolytic anemia
Hemolysis shortens the usual RBC lifespan of roughly 120 days. [11] If marrow production fully compensates, hemoglobin can remain normal: that is compensated hemolysis, not necessarily anemia. Look for a trajectory and a combination of reticulocytosis, increased indirect bilirubin and LDH, and decreased haptoglobin. Reticulocytes may be low early in an episode or when infection, nutrient deficiency or marrow failure limits replacement. LDH also rises with tissue injury and ineffective erythropoiesis. Liver disease can lower haptoglobin synthesis; inflammation can increase it. No single marker establishes or excludes every episode. [1]
Two places where an RBC can disappear
Within the circulation
RBC rupture releases hemoglobin into plasma. Liver-produced haptoglobin binds free hemoglobin; macrophage CD163 mediates uptake of the complex. [27] When binding capacity is exceeded, hemoglobinemia and hemoglobinuria can appear. Examples include complement-mediated PNH, severe oxidant injury and mechanical trauma.
Within macrophages
Splenic or hepatic macrophages ingest damaged or coated cells. Heme processing increases indirect bilirubin; chronic destruction can produce pigment gallstones and splenomegaly. Warm IgG disease and hereditary spherocytosis often emphasize splenic clearance.
These are mechanisms that can overlap, not exclusive disease bins. Bilirubin may rise in either setting. Cold-antibody disease often causes hepatic extravascular clearance even though complement participates. [1][3]
Hemosiderin in urinary epithelial cells supports chronic intravascular hemolysis. It is a different observation from free urinary hemoglobin. [31] Chronic intravascular hemolysis can cause substantial urinary iron loss and iron deficiency, particularly in PNH; this differs from efficient iron recycling during macrophage clearance. [28]
A urine dipstick detects heme activity. Positive blood with few or no RBCs on microscopy can represent hemoglobin or myoglobin. Plasma hemolysis studies and creatine kinase distinguish RBC destruction from muscle injury. Repetitive foot impact can cause transient intravascular hemolysis in runners, but exertion also raises the possibility of rhabdomyolysis. Do not label every dark post-exercise urine sample hemoglobinuria.
Smear shape narrows the investigation without completing it. Spherocytes occur in inherited and immune disease; schistocytes indicate fragmentation but not its cause; bite cells suggest removal of oxidized hemoglobin inclusions. Target cells occur in hemoglobin disorders and liver disease. Acanthocytes suggest membrane lipid abnormalities, including advanced liver disease; tear-drop cells can suggest marrow distortion or infiltration. Neither is a universal marker of hemolysis. [1]
Try it here · Checkpoint 1 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 2
Show answer and explanations for case 2
A. Hemoglobin from proven foot-strike hemolysis (Why this does not fit)
Exercise alone does not prove RBC destruction; the supplied CK and hemolysis studies favor muscle injury.
B. Unconjugated bilirubin (Why this does not fit)
Dipstick blood detects heme activity, and unconjugated bilirubin is not filtered into urine.
C. Myoglobin from muscle injury (Best answer)
The marked CK increase with muscle exertion and absent hemolysis pattern supports rhabdomyolysis.
D. Intact urinary RBCs (Why this does not fit)
Microscopy does not show RBCs despite dipstick heme positivity.
Takeaway: Dipstick heme needs microscopy and the appropriate plasma studies.
Immune coating: read the DAT in its clinical setting
The direct antiglobulin test, or DAT, tests the patient's RBCs for attached immunoglobulin and complement. A positive result without biochemical or clinical hemolysis does not establish autoimmune hemolytic anemia. Conversely, a small minority of immune cases require more sensitive investigation after a negative routine DAT. Distinguish an autoantibody from alloantibodies after pregnancy or transfusion and from drug-dependent reactions. [1][2]
Antibody behavior predicts a different clearance pathway
Pattern
Typical DAT
Mechanism and context
PatternWarm immune hemolysis
Typical DATIgG, sometimes with C3
Mechanism and contextIgG-coated cells are commonly cleared in spleen. Consider primary disease, SLE, CLL and drugs.
PatternCold agglutinin hemolysis
Typical DATC3d; IgG usually absent or weak
Mechanism and contextIgM binds in cooler tissue and activates complement. After warming, IgM may detach while complement remains; C3b-coated cells are often cleared in liver.
PatternNonimmune hemolysis
Typical DATUsually negative
Mechanism and contextInvestigate membrane, enzyme, hemoglobin, mechanical, infectious and GPI-anchor disorders.
Warm disease often produces spherocytes when macrophages partially ingest the RBC membrane. Corticosteroids remain a principal initial therapy; severe disease or inadequate early response may justify rituximab. Identify secondary causes and discontinue a culprit drug. Methyldopa can provoke a true warm autoantibody. Classic high-dose penicillin reactions can be drug-dependent; not every antibiotic-associated hemolysis follows that same mechanism. [29] Life-threatening anemia requires coordinated urgent transfusion support rather than waiting indefinitely for an uncomplicated crossmatch. [2][5]
Cold agglutinin disease often reflects a clonal B-cell disorder; a transient cold agglutinin syndrome can follow Mycoplasma or other infection. CLL does not automatically mean a cold IgM mechanism: classify the actual antibody. Thermal amplitude, the highest temperature at which an antibody reacts, helps determine pathogenicity. An antibody active only at very cold laboratory temperatures is different from one reactive near temperatures reached in peripheral tissues.
Cold protection and treatment of an underlying condition matter, while routine corticosteroids are much less useful than in warm disease. Disease-directed options include B-cell therapy and, for adult CAD hemolysis, the C1s inhibitor sutimlimab. Its infection precautions include updating recommended encapsulated-bacterial vaccinations before therapy when possible; vaccination does not eliminate serious infection risk. [2][3][4]
Keep recipient plasma and patient cells straight
What the two antiglobulin approaches actually examine
DAT: coating already on cells
Patient RBCs → test for bound IgG or complement → interpret with evidence of destruction.
A serologic RBC crossmatch combines recipient plasma with donor RBCs. It does not primarily screen donor plasma for antibodies against the recipient. [5]
An anamnestic alloantibody response can cause a delayed hemolytic transfusion reaction days to weeks after apparently compatible blood. In sickle disease, hyperhemolysis may destroy both donor and patient cells, dropping hemoglobin below the pretransfusion value. Obtain specialist and transfusion-service input promptly; additional RBCs can worsen destruction and are generally avoided unless life-threatening anemia makes transfusion necessary. ASH supports immunosuppressive treatment for ongoing hyperhemolysis, individualized to severity. [13]
Maternal IgG can cross the placenta and target fetal RBC antigens. Rh disease requires maternal sensitization, which can precede a first pregnancy through transfusion; ABO disease can also occur in a first pregnancy. An Rh-negative mother and Rh-positive infant alone do not establish anti-D disease: identify the antibody. Anti-D prophylaxis prevents sensitization in appropriate nonsensitized patients and does not erase an established immune anti-D response.
In newborns, jaundice during the first 24 hours demands prompt assessment. It is not automatically physiologic and does not prove a specific hemolytic cause. The AAP algorithm applies to infants born at least 35 weeks; earlier gestations require separate neonatal guidance. Treatment thresholds depend on measured bilirubin, age in hours, gestational age and neurotoxicity risk. [5][6]
Try it here · Checkpoint 2 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 10
Show answer and explanations for case 10
A. The infant must first make its own anti-D (Why this does not fit)
Maternal alloantibody can cause disease before the infant develops such an immune response.
B. The mother must have had a prior pregnancy (Why this does not fit)
Prior transfusion can sensitize her before a first pregnancy.
C. Maternal IgG crosses the placenta (Best answer)
Immune anti-D is IgG and can enter fetal circulation to target D-positive RBCs.
D. Maternal IgM readily crosses the placenta (Why this does not fit)
IgM is not the immunoglobulin class that normally crosses in this manner.
Takeaway: Identify maternal antibody specificity and class rather than relying on pregnancy number.
Inherited RBC vulnerability: membrane, energy or hemoglobin
Membrane geometry and energy
Hereditary spherocytosis often involves ankyrin, spectrin, band 3 or protein 4.2, disrupting attachment of the membrane to its supporting skeleton. Membrane area falls relative to volume, reducing deformability during splenic passage. Familial jaundice, pigment stones, spherocytes and a negative DAT support investigation with EMA binding or other specialist tests. Osmotic fragility can also increase in immune spherocytosis and is not by itself a clean separator. Splenectomy helps selected clinically significant cases but leaves the inherited RBC defect intact and introduces infection and thrombotic risks. Spherocytes may remain; Howell-Jolly bodies can appear after splenic function is lost. [7][8]
Hereditary elliptocytosis commonly affects horizontal interactions within the spectrin-based skeleton and may produce many elliptocytes with little hemolysis. Pyruvate kinase deficiency instead impairs glycolytic ATP production in RBCs, which lack mitochondria. Reduced energy compromises membrane function and survival. It is usually autosomal recessive and can cause chronic nonspherocytic hemolysis; echinocytes are suggestive, not diagnostic. Increased 2,3-BPG can favor oxygen unloading. Confirm suspected enzyme disease with appropriate enzyme and genetic testing, accounting for transfusion and cell age. [9][20][1]
Oxidative defense
G6PD supplies NADPH through the pentose phosphate pathway, supporting reduced glutathione. Oxidative stress can denature hemoglobin into Heinz bodies, best seen with a supravital stain. Splenic removal of these inclusions produces bite cells. Infection, fava beans and specific medications can precipitate episodes. X-linked inheritance does not restrict disease to males; heterozygous females can have substantial deficiency because X inactivation varies. Testing during reticulocytosis or after transfusion may miss the deficiency and can require repeat assessment after recovery. [1][10]
Use drug-specific evidence rather than a blanket list of entire drug classes. CPIC identifies dapsone, rasburicase and primaquine at standard daily radical-cure doses among high-risk exposures in G6PD deficiency, while sulfamethoxazole falls in a low-to-no added-risk category at standard use. Chronic nonspherocytic hemolytic anemia requires additional caution with any medication. Dapsone can also cause oxidant hemolysis in someone without G6PD deficiency. Stop the suspected trigger and assess severity rather than assuming every drug-related hemolysis is antibody mediated. [10]
Protein structure is different from production quantity
Each hemoglobin tetramer contains four globin subunits, each associated with an iron-containing heme group. Hemoglobin carries oxygen inside the RBC; plasma haptoglobin instead binds hemoglobin released after cell rupture. HbA is alpha-two beta-two, HbA2 alpha-two delta-two and HbF alpha-two gamma-two. Under physiological conditions with 2,3-BPG, HbF binds oxygen more avidly than HbA, supporting maternal-to-fetal oxygen transfer. [30] HBB is on chromosome 11; HBA1 and HBA2 are on chromosome 16, giving four alpha-gene copies across the pair. [23] Thalassemia reduces production of a globin subunit, causing imbalance, ineffective erythropoiesis and variable hemolysis.
HbS replaces glutamate with valine at beta position 6; deoxygenated HbS polymerizes, promoting sickling, vascular obstruction and hemolysis. HbC replaces that glutamate with lysine and can produce target cells and characteristic crystals. HbSC is a sickle disease genotype, not a benign carrier state. [22][19][1]
Recognize the pattern that changes the immediate response
Thalassemia severity depends on how much useful globin can be made. Beta trait often combines marked microcytosis, relatively preserved RBC number and increased HbA2; iron deficiency can coexist and lower HbA2. RDW and the Mentzer index are supportive screening observations, not definitive tests. Beta thalassemia major becomes apparent as gamma-containing HbF declines in infancy. Excess unmatched alpha globin damages precursors as well as circulating cells, explaining ineffective erythropoiesis, marrow expansion, extramedullary hematopoiesis and hemolysis. Regular transfusion can require chelation for iron overload. [19]
For alpha thalassemia, one inactive copy is commonly silent, two produce trait, three commonly produce HbH disease and four produce Hb Bart syndrome. HbH is a beta-four tetramer after birth; Hb Bart is gamma-four and binds oxygen too tightly for effective fetal delivery. Adult electrophoresis can be normal in alpha trait. Whether two inactive copies lie on one chromosome or one on each changes reproductive risk. Fetal transfusion has allowed survival in selected Hb Bart pregnancies, replacing the old absolute fatality claim. [23]
In sickle disease, painful swollen hands and feet in infancy reflect dactylitis. [32] A new pulmonary infiltrate with fever, respiratory symptoms or hypoxemia suggests acute chest syndrome and requires urgent care; severe cases can need RBC exchange. Repeated splenic injury increases susceptibility to encapsulated organisms. A suddenly enlarging spleen with anemia and reticulocytosis suggests sequestration, while almost absent reticulocytes after infection suggest parvovirus B19-related aplastic crisis.
Splenic function and sequestration risk depend on genotype and age, so an age cutoff alone is unreliable. Hydroxyurea increases HbF and reduces complications. Voxelotor was withdrawn in 2024 and should not be presented as a current treatment option. [11][12][13][14]
PNH is an acquired hematopoietic stem-cell disorder, commonly involving PIGA and loss of GPI-anchored proteins including CD55 and CD59. Complement-mediated hemolysis, marrow failure and unusual thrombosis may coexist. Hemolysis need not occur at night. Flow cytometry examines multiple GPI-linked markers in RBC and white-cell populations; FLAER-based granulocyte and monocyte assessment avoids underestimating clone size from transfused or selectively destroyed RBCs. The historical Ham test is obsolete. [15]
Complement inhibition can control clinically important PNH hemolysis. C5 inhibitors such as eculizumab and ravulizumab and proximal therapy such as the factor B inhibitor iptacopan have different targets; they are not interchangeable in every clinical setting. [21] Thrombosis reflects several interacting effects of complement activation, blood-cell activation and free hemoglobin, rather than a single exclusive explanation. Complement inhibition increases meningococcal risk even after vaccination; vaccination, possible antimicrobial prophylaxis and urgent assessment of infection symptoms remain necessary. [15][16]
Schistocytes with thrombocytopenia and organ injury raise concern for thrombotic microangiopathy. Severe ADAMTS13 deficiency, usually activity below 10%, supports TTP. Do not wait for the complete historical pentad or a delayed assay result before treating strongly suspected immune TTP: obtain the pretreatment sample and arrange urgent plasma exchange with corticosteroids and specialist-directed adjuncts such as caplacizumab and rituximab.
The 2025 ISTH update preserves these immune TTP principles and adds stronger support for recombinant ADAMTS13 in congenital TTP remission. The 2026 US boxed-warning update addresses neutralizing antibodies and serious outcomes including death. Such antibodies can reduce response to recombinant or plasma-derived ADAMTS13. Check activity and neutralizing antibodies before treatment and periodically during therapy under specialist care. [26][24][17]
HUS often emphasizes kidney injury, including after Shiga-toxin diarrhea, but neurologic features do not exclude it. [25] DIC is systemic coagulation activation with consumption and requires assessment of coagulation tests, fibrinogen trends and the precipitating disease. Prosthetic-valve hemolysis is large-vessel mechanical injury, not strictly a small-vessel microangiopathy. Malaria can cause both intravascular and extravascular destruction. Obtain urgent thick and thin smears or appropriate rapid testing after a compatible exposure; severe malaria, including parasitemia at least 5% in CDC guidance, requires IV artesunate. [1][18]
Try it here · Checkpoint 3 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 20
Show answer and explanations for case 20
A. Acute chest syndrome (Best answer)
A new infiltrate with respiratory compromise in sickle disease fits ACS and severe disease may need exchange transfusion.
B. Uncomplicated pain crisis alone (Why this does not fit)
The new lung findings and hypoxemia exceed an isolated pain episode.
C. Uncomplicated viral upper respiratory infection (Why this does not fit)
The pulmonary infiltrate and increasing oxygen requirement indicate lower respiratory organ involvement and meet ACS criteria.
D. Isolated opioid hypoventilation (Why this does not fit)
Opioids may contribute to hypoxemia, but do not adequately explain the fever and new infiltrate that require ACS care.
Takeaway: New pulmonary findings change a sickle pain admission into an urgent respiratory problem.
